Bio-Path Holdings, Inc. (BPTH)

Market Cap	3.87M
Revenue (ttm)	n/a
Net Income (ttm)	-13.96M
Shares Out	2.08M
EPS (ttm)	-26.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,889
Open	1.890
Previous Close	1.940
Day's Range	1.850 - 1.945
52-Week Range	1.850 - 35.800
Beta	0.31
Analysts	Strong Buy
Price Target	40.00 (+2,050.54%)
Earnings Date	Aug 13, 2024

About BPTH

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also de...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: BPTH

Analyst Forecast

According to 2 analysts, the average rating for BPTH stock is "Strong Buy." The 12-month stock price forecast is $40.0, which is an increase of 2,050.54% from the latest price.

Price Target

$40.0

(2,050.54% upside)

Analyst Consensus: Strong Buy